Monika Hämmerle

Dr. Monika Hämmerle

Institute of Pathology, University Hospital Halle, Halle (Saale), Germany
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2013 in Cancer Research
Verified
Journal Article
Closed access
PDF file
TGTony Gutschner
Tony Gutschner
MHMonika Hämmerle
Monika Hämmerle
MEMoritz Eißmann
Moritz Eißmann
JHJeff Hsu
Jeff Hsu
YKYoungsoo Kim
Youngsoo Kim
SDSven Diederichs
Sven Diederichs
The long noncoding RNA MALAT1 (metastasis-associated lung adenocarcinoma transcript 1), also known as MALAT-1 or NEAT2 (nuclear-enriched abundant transcript 2), is a highly conserved nuclear noncoding RNA (ncRNA) and a predictive marker for metastasis development in lung cancer. To uncover its functional importance, we developed a MALAT1 knockout model in human lung tumor cells by genomically integrating RNA destabilizing elements using zinc finger nucleases. The achieved 1,000-fold MALAT1 silencing provides a unique loss-of-function model. Proposed mechanisms of action include regulation of splicing or gene expression. In lung cancer, MALAT1 does not alter alternative splicing but actively regulates gene expression including a set of metastasis-associated genes. Consequently, MALAT1-deficient cells are impaired in migration and form fewer tumor nodules in a mouse xenograft. Antisense oligonucleotides (ASO) blocking MALAT1 prevent metastasis formation after tumor implantation. Thus, targeting MALAT1 with ASOs provides a potential therapeutic approach to prevent lung cancer metastasis with this ncRNA serving as both predictive marker and therapeutic target. Finally, regulating gene expression, but not alternative splicing, is the critical function of MALAT1 in lung cancer metastasis. In summary, 10 years after the discovery of the lncRNA MALAT1 as a biomarker for lung cancer metastasis, our loss-of-function model unravels the active function of MALAT1 as a regulator of gene expression governing hallmarks of lung cancer metastasis. Cancer Res; 73(3); 1180–9. ©2012 AACR.

26 March 2013 in Journal of Molecular Medicine
Verified
Journal Article
Closed access
PDF file
TGTony Gutschner
Tony Gutschner
MHMonika Hämmerle
Monika Hämmerle
SDSven Diederichs
Sven Diederichs

1 November 2016 in Cell Metabolism
Verified
Journal Article
Closed access
LYLifeng Yang
Lifeng Yang
Abhinav AchrejaAbhinav Achreja
Abhinav Achreja
TYTsz-Lun Yeung
Tsz-Lun Yeung
LMLingegowda S. Mangala
Lingegowda S. Mangala
DJDahai Jiang
Dahai Jiang
DNDeepak Nagrath
Deepak Nagrath

20 September 2013 in Hepatology
Verified
Journal Article
Open access
PDF file
LQLuca Quagliata
Luca Quagliata
MMMatthias Matter
Matthias Matter
Salvatore PiscuoglioSalvatore Piscuoglio
Salvatore Piscuoglio
LALeila Arabi
Leila Arabi
CRChristian Ruiz
Christian Ruiz
LTLuigi Terracciano
Luigi Terracciano
Hepatocellular carcinoma (HCC) is among the leading causes of cancer-related death. Despite the advances in diagnosis and management of HCC, the biology of this tumor remains poorly understood. Recent evidence highlighted long noncoding RNAs (lncRNAs) as crucial determinants of HCC development. In this study we report the lncRNA HOXA transcript at the distal tip (HOTTIP) as significantly up-regulated in HCC specimens. The HOTTIP gene is located in physical contiguity with HOXA13 and directly controls the HOXA locus gene expression by way of interaction with the WDR5/MLL complex. HOX genes encode transcription factors regulating embryonic development and cell fate. We previously described HOX genes deregulation to be involved in hepatocarcinogenesis. Indeed, we observed the marked up-regulation of HOXA13 in HCC. Here, by correlating clinicopathological and expression data, we demonstrate that the levels of HOTTIP and HOXA13 are associated with HCC patients' clinical progression and predict disease outcome. In contrast to the majority of similar studies, our data were obtained from snap-frozen needle HCC biopsies (n = 52) matched with their nonneoplastic counterparts collected from patients who had not yet received any HCC-tailored therapeutic treatments at the time of biopsy. In addition, taking advantage of gain and loss of function experiments in liver cancer-derived cell lines (HuH-6 and HuH-7), we uncover a novel bidirectional regulatory loop between HOTTIP/HOXA13. Conclusion: Our study highlights the key role of HOTTIP and HOXA13 in HCC development by associating their expression with metastasis and survival in HCC patients, provides novel insights on the function of lncRNA-driven hepatocarcinogenesis, and paves the way for further investigation about the possible role of HOTTIP as a predictive biomarker of HCC. (HEPATOLOGY 2014;59:911–923)

1 August 2012 in RNA Biology
Verified
Journal Article
Open access
MEMoritz Eißmann
Moritz Eißmann
TGTony Gutschner
Tony Gutschner
MHMonika Hämmerle
Monika Hämmerle
SGStefan Günther
Stefan Günther
MCMaïwen Caudron-Herger
Maïwen Caudron-Herger
SDSven Diederichs
Sven Diederichs
The metastasis-associated lung adenocarcinoma transcript 1, MALAT1, is a long non-coding RNA (lncRNA) that has been discovered as a marker for lung cancer metastasis. It is highly abundant, its exp...

1 February 2016 in Cell Reports
Verified
Journal Article
Open access
TGTony Gutschner
Tony Gutschner
MHMonika Hämmerle
Monika Hämmerle
GGGiannicola Genovese
Giannicola Genovese
GDGiulio F. Draetta
Giulio F. Draetta
LCLynda Chin
Lynda Chin
CRISPR/Cas9 induces DNA double-strand breaks that are repaired by cell-autonomous repair pathways, namely, non-homologous end-joining (NHEJ), or homology-directed repair (HDR). While HDR is absent in G1, NHEJ is active throughout the cell cycle and, thus, is largely favored over HDR. We devised a strategy to increase HDR by directly synchronizing the expression of Cas9 with cell-cycle progression. Fusion of Cas9 to the N-terminal region of human Geminin converted this gene-editing protein into a substrate for the E3 ubiquitin ligase complex APC/Cdh1, resulting in a cell-cycle-tailored expression with low levels in G1 but high expression in S/G2/M. Importantly, Cas9-hGem(1/110) increased the rate of HDR by up to 87% compared to wild-type Cas9. Future developments may enable high-resolution expression of genome engineering proteins, which might increase HDR rates further, and may contribute to a better understanding of DNA repair pathways due to spatiotemporal control of DNA damage induction.